Business Wire

SMITHS-DETECTION

24.3.2017 11:02:55 CET | Business Wire | Press release

Share
Smiths Detection to Supply Dutch Airports with Advanced Hold Baggage Scanners

Smiths Detection has won a significant contract to supply Amsterdam Airport Schiphol with new hold baggage screening equipment which complies with the latest EU regulations – EDS Standard 3. The contract includes 24 HI-SCAN 10080 XCT systems for installation at Schiphol, with the option for a further six to be deployed at Lelystad, Rotterdam - The Hague and Eindhoven airports.

The next-generation HI-SCAN 10080 XCT scanner uses high-resolution X-ray technology, medical quality computed tomography and advanced detection algorithms which combine to deliver exceptional levels of security. It not only detects the explosive threats currently specified by the new standard, but can also be upgraded to meet future requirements to identify evolving threats such as homemade explosives. Delivery of the new equipment will take place over the next five years.

Schiphol is Europe's third-largest airport in terms of passenger numbers and cargo volume and has won around 200 international awards over the last 30 years. It is widely recognised as one of the world’s best international airports and handles a significant proportion of transit passengers - which makes a high-speed, high volume, hold baggage system critical to screening efficiency.

“Schiphol is renowned for staying at the forefront of new developments and innovative technologies and we are delighted Smiths Detection has been chosen to upgrade their hold baggage screening,” said Tony Tielen, Vice President EMEA, Smiths Detection. “The contract is testament to our commitment to delivering the highest levels of security and operational performance, as well as representing significant progress in the continued expansion of the Smiths Detection footprint.”

Ends

Notes to editors

HI-SCAN 10080 XCT key features:

  • EU/ECAC EDS Standard 3 approved
  • Laboratory certified for high-speed checked baggage screening by the United
    • States Transportation Security Administration (TSA)
  • Belt speed of 0.5m/sec (98.5ft/min)
  • High throughput of up to 1800 bags per hour
  • Large tunnel capable of screening objects 100 x 80 cm (39.4 x 31.5in)

A dual-energy X-ray line scanner with full 3D volumetric Computed Tomography (CT) imaging and reconstruction, the HI-SCAN 10080 XCT is the next generation high-speed checked baggage explosives detection system (EDS).

With a belt speed of 0.5m/sec (98.5ft/min) and a large 1070 x 810mm (42.1 x 31.9in) rectangular tunnel, the HI-SCAN 10080 XCT provides the most economical solution for airport checked baggage screening requirements. This combination of belt speed and tunnel size will provide baggage handling systems the capability to process a throughput of up to 1800 bags/hour with object sizes of up to 1000 x 800 mm (39.4 x 31.5in).

The HI-SCAN 10080 XCT is designed to integrate easily into newly implemented Hold Baggage System (HBS) configurations or as a replacement for current baggage handling systems.

Further details on the Smiths Detection HI-SCAN 10080 XCT can be found here: http://www.smithsdetection.com/index.php?option=com_k2&view=item&id=157:hi-scan-10080-xct&Itemid=101&lang=en#.WKwoEoXXLmg

About Smiths Detection

Smiths Detection, part of Smiths Group, is a global leader in threat detection and screening technologies for military, air transportation, homeland security and emergency response markets. Our experience and history across more than 40 years at the frontline, enables us to provide unrivalled levels of expertise to detect and identify constantly changing chemical, radiological, nuclear and explosive threats, as well as weapons, dangerous goods, contraband and narcotics.

Our goal is simple – to provide security, peace of mind and freedom of movement upon which the world depends. For more information visit www.smithsdetection.com

Contact:

Smiths Detection
Karen Kulinski
Director Communications and Marketing (EMEA)
+49 (0)611 9412 422
karen.kulinski@smithsdetection.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye